Synthesis, Anticancer, and Antibacterial Activity of Betulinic and Betulonic Acid C-28-Triphenylphosphonium Conjugates with Variable Alkyl Linker Length
Background:
Conjugation of triterpenoids such as betulinic acid 1 with the Triphenylphosphonium (TPP) group is a powerful approach to generating medicinal compounds. Their development proposes structure optimization in respect of availability and activity towards target cells and organelles. Selection of 1 or its precursor betulonic acid 2 and the optimal linker is of particular importance for drug candidate identification among the TPP-triterpenoid conjugates.
Objective:
In this study, new C-28-TPP conjugated derivatives of 1 and 2 with the alkyl/alkoxyalkyl linkers of variable length were synthesized and compared regarding their anticancer, antibacterial, and mitochondriatargeted effects.
Methods:
The TPP conjugates of 1 and 2 [6a-f, 7a-f] were synthesized by the reaction of halogenalkyl esters [3a-f, 4a-f, 5] with triphenylphosphine in acetonitrile upon heating. Cytotoxicity (MTT assay), antibacterial activity (microdilution assay), and mitochondrial effects (flow cytofluorometry) were studied.
Results:
Conjugation with the TPP group greatly increased the cytotoxicity of the triterpenoids up to 30 times. The conjugates were up to 10-17 times more active against MCF-7 (IC50 = 0.17μM, 72h, 6c) and PC-3 (IC50 = 0.14μM, 72h, 6a) cancer cells than for human skin fibroblasts. The enhanced antibacterial (bactericidal) activity of the TPP-triterpenoid conjugates with MIC for Gram-positive bacteria as low as 2μM (6a, 7a) was for the first time revealed. The conjugates were found to effectively inhibit fluorescence of 2′,7′-dichlorofluorescin probe in the cytosol upon oxidation, decrease transmembrane potential, and increase superoxide radical level in mitochondria.
Conclusion:
Relationships between the effects and structure of the TPP-triterpenoid conjugates were evaluated and are discussed. Based on the results, 6a can be selected for further preclinical investigation as a potential anticancer compound.
Top-30
Journals
|
1
2
3
|
|
|
Molecules
3 publications, 10.34%
|
|
|
Russian Journal of General Chemistry
3 publications, 10.34%
|
|
|
Medicinal Chemistry Research
2 publications, 6.9%
|
|
|
Russian Chemical Bulletin
2 publications, 6.9%
|
|
|
Mendeleev Communications
2 publications, 6.9%
|
|
|
Plants
2 publications, 6.9%
|
|
|
International Journal of Molecular Sciences
2 publications, 6.9%
|
|
|
Antibiotics
1 publication, 3.45%
|
|
|
Cancers
1 publication, 3.45%
|
|
|
Journal of Molecular Structure
1 publication, 3.45%
|
|
|
Current Research in Pharmacology and Drug Discovery
1 publication, 3.45%
|
|
|
Chemical Research in Toxicology
1 publication, 3.45%
|
|
|
ACS Omega
1 publication, 3.45%
|
|
|
Phosphorus, Sulfur and Silicon and the Related Elements
1 publication, 3.45%
|
|
|
Cancer Prevention Research
1 publication, 3.45%
|
|
|
Journal of Natural Products
1 publication, 3.45%
|
|
|
Russian Chemical Reviews
1 publication, 3.45%
|
|
|
Future Medicinal Chemistry
1 publication, 3.45%
|
|
|
Biomedicines
1 publication, 3.45%
|
|
|
Journal of Antibiotics
1 publication, 3.45%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
|
|
|
MDPI
10 publications, 34.48%
|
|
|
Springer Nature
5 publications, 17.24%
|
|
|
Pleiades Publishing
3 publications, 10.34%
|
|
|
American Chemical Society (ACS)
3 publications, 10.34%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
2 publications, 6.9%
|
|
|
Elsevier
2 publications, 6.9%
|
|
|
Taylor & Francis
2 publications, 6.9%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 3.45%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.45%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
